State Street Holds 5.6% Of Intellia As The Company Prepares For A Potential Drug Launch
Intellia is building commercial infrastructure while losing money, with an FDA target decision date of March 10, 2027.
State Street reported a 5.6% stake in Intellia Therapeutics, which develops CRISPR gene-editing treatments for severe diseases, in a passive ownership disclosure filed Tuesday. The position comes as Intellia prepares for a potential launch of its one-time hereditary angioedema treatment while continuing to lose money.
7.8 Million Shares, Passive Ownership
State Street's position totaled 7,809,060 common shares as of September 30, 2026. It reported shared power to direct the sale or transfer of that entire position and shared voting authority over 7,473,384 shares.
State Street certified that the investment arose from ordinary business activities and was not intended to change or influence Intellia's control. The disclosure therefore describes a passive holding, rather than a campaign to steer management.
Launch Spending Meets Quarterly Losses
Intellia's third-quarter revenue fell 48% from a year earlier to $7.2 million, and it lost $0.91 per share. General and administrative expenses climbed about 51% to $46.1 million; the company attributed the increase primarily to commercial infrastructure, legal costs and stock-based compensation.
Cash, cash equivalents and marketable securities totaled $614.8 million on September 30, compared with $628.4 million on June 30. Management expects its resources to support operations at least into 2028. A September loan agreement with OrbiMed provides up to $400 million as Intellia prepares for possible commercialization.
Intellia had a market value of $1.7 billion as of 8:47 a.m. ET Tuesday.
A Single-Infusion Treatment Awaits Review
Intellia's experimental hereditary angioedema treatment, lonvoguran ziclumeran, or lonvo-z, targets a disease that causes recurring swelling attacks. Its other lead treatment, nexiguran ziclumeran, targets transthyretin amyloidosis, in which protein buildup damages organs and tissues. Both are designed for a single intravenous infusion and are in late-stage clinical development.
The company develops treatments independently and with partners, including Regeneron, and licenses technology under arrangements involving payments, royalties and shared costs. Its trials operate across multiple countries. Regeneron shares approximately 25% of worldwide development costs and commercial profits for the transthyretin amyloidosis program.
The FDA's target decision date for lonvo-z is March 10, 2027. Management expects to complete commercial preparations before that date.
Intellia is spending to prepare for commercialization; the potential launch still depends on the FDA's decision.
Sources
- SCHEDULE 13G — STATE STREET CORPORATION re: INTELLIA THERAPEUTICS INC (NTLA) — SEC EDGAR
- Intellia Therapeutics (NTLA) Stock Could Look Stretched On Phase 3 Trial Progress — Yahoo Finance
- Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus — Yahoo Finance
- Intellia Therapeutics, Inc. (NTLA) Stock Forecasts — Yahoo Finance
- Intellia Therapeutics to Present at Jefferies Global — globenewswire.com
- Intellia Therapeutics Reports Inducement Grants Under — globenewswire.com